Saturday, May 15, 2021 8:06:25 AM
Q1 was all but over when this was released....it's all good going forward.
SOHM, Inc., Receives a Mandate for Development, Manufacturing, and Supply skincare topical products.
03/25/2021
CHINO HILLS, CA—March 25, 2021 – SOHM, Inc. (Pink Sheets: SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today that the company has received a mandate for development, manufacturing and supply seven new skincare SKU for its human prescription topical products.
Today, Mr. Baron Night, CEO announce that SOHM has received a mandate from one of its customers for the development, manufacturing, and supply of seven of the customer’s new products. These products are human prescription products and are in use in skin care and acne care. These mandates will be strengthening the company’s efforts to continue its B2B business under a private label agreement.
This mandate and scope of the project is just the beginning of launching its products into major pharmacy retail stores. SOHM’s customer will be distributing them to various pharmacy chain stores that include Publix, CVS and Wal-Mart throughout the United States.
Upon execution of these mandates in the coming months, the company will have 14 different compositions and SKU’s and different categories of products which include Gel, Cleanser, Cream, suspension, etc. The company targets to develop every month at least two products and finish the development and supply in the next 4 to 5 months.
Mr. Baron Night, CEO said, “SOHM is very pleased to have received this new mandate and project. Upon completion of these mandates, the company’s revenue stream will be having very positive growth in 2021 and the coming years. This represents an annualized commitment once this order is executed and the product is on the shelf of pharmacies distribution and pharmacy retail stores”.
The management continue and assures that SOHM achieves its target for higher revenue growth in 2021 compared to previous years.
SOHM, Inc., Receives a Mandate for Development, Manufacturing, and Supply skincare topical products.
03/25/2021
CHINO HILLS, CA—March 25, 2021 – SOHM, Inc. (Pink Sheets: SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today that the company has received a mandate for development, manufacturing and supply seven new skincare SKU for its human prescription topical products.
Today, Mr. Baron Night, CEO announce that SOHM has received a mandate from one of its customers for the development, manufacturing, and supply of seven of the customer’s new products. These products are human prescription products and are in use in skin care and acne care. These mandates will be strengthening the company’s efforts to continue its B2B business under a private label agreement.
This mandate and scope of the project is just the beginning of launching its products into major pharmacy retail stores. SOHM’s customer will be distributing them to various pharmacy chain stores that include Publix, CVS and Wal-Mart throughout the United States.
Upon execution of these mandates in the coming months, the company will have 14 different compositions and SKU’s and different categories of products which include Gel, Cleanser, Cream, suspension, etc. The company targets to develop every month at least two products and finish the development and supply in the next 4 to 5 months.
Mr. Baron Night, CEO said, “SOHM is very pleased to have received this new mandate and project. Upon completion of these mandates, the company’s revenue stream will be having very positive growth in 2021 and the coming years. This represents an annualized commitment once this order is executed and the product is on the shelf of pharmacies distribution and pharmacy retail stores”.
The management continue and assures that SOHM achieves its target for higher revenue growth in 2021 compared to previous years.
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
